Piper Sandler Downgrades Supernus Pharmaceuticals to Neutral, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has downgraded Supernus Pharmaceuticals from Overweight to Neutral and reduced its price target from $41 to $36.

September 11, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler downgraded Supernus Pharmaceuticals from Overweight to Neutral, reducing the price target from $41 to $36. This suggests a less optimistic outlook on the stock.
The downgrade from Overweight to Neutral by Piper Sandler indicates a shift in sentiment, suggesting that the stock may not perform as well as previously expected. The lowered price target further supports this view, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100